Literature DB >> 34193282

Can preoperative liver MRI with gadoxetic acid help reduce open-close laparotomies for curative intent pancreatic cancer surgery?

Kartik S Jhaveri1, Ali Babaei Jandaghi2, Seng Thipphavong3, Osvaldo Espin-Garcia4,5, Anna Dodd6, Shawn Hutchinson6, Trevor W Reichman7, Carol-Anne Moulton7, Ian D McGilvary8, Steven Gallinger8.   

Abstract

OBJECTIVES: To evaluate gadoxetic acid-enhanced liver MRI (EOB-MRI) versus contrast-enhanced computed tomography (CECT) for preoperative detection of liver metastasis (LM) and reduction of open-close laparotomies for pancreatic ductal adenocarcinoma (PDAC).
METHODS: Sixty-six patients with PDAC had undergone preoperative EOB-MRI and CECT. LM detection by EOB-MRI and CECT and their impact on surgical planning, open-close laparotomies were compared by clinical and radiology reports and retrospective analysis of imaging by two blinded independent readers. Histopathology or imaging follow-up was the reference standard. Statistical analysis was performed at patient and lesion levels with two-sided McNemar tests.
RESULTS: EOB-MRI showed higher sensitivity versus CECT (71.7% [62.1-80.0] vs. 34% [25.0-43.8]; p = 0.009), comparable specificity (98.6%, [96.9-99.5] vs. 100%, [99.1-100], and higher AUROC (85.1%, [80.4-89.9] vs. 66.9%, [60.9-73.1]) for LM detection. An incremental 7.6% of patients were excluded from surgery with a potential reduction of up to 13.6% in futile open-close laparotomies due to LM detected on EOB-MRI only.
CONCLUSIONS: Preoperative EOB-MRI has superior diagnostic performance in detecting LM from PDAC. This better informs surgical eligibility with potential reduction of futile open-close laparotomies from attempted curative intent pancreatic cancer surgery.

Entities:  

Keywords:  CT scan; Gadoxetic acid-enhanced MRI; Liver metastasis; Pancreatic adenocarcinoma; Whipple procedure

Year:  2021        PMID: 34193282     DOI: 10.1186/s40644-021-00416-4

Source DB:  PubMed          Journal:  Cancer Imaging        ISSN: 1470-7330            Impact factor:   3.909


  23 in total

1.  Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement.

Authors:  Mark P Callery; Kenneth J Chang; Elliot K Fishman; Mark S Talamonti; L William Traverso; David C Linehan
Journal:  Ann Surg Oncol       Date:  2009-04-24       Impact factor: 5.344

Review 2.  Consensus statements from a multidisciplinary expert panel on the utilization and application of a liver-specific MRI contrast agent (gadoxetic acid).

Authors:  Kartik Jhaveri; Sean Cleary; Pascale Audet; Fady Balaa; Deepak Bhayana; Kelly Burak; Silvia Chang; Elijah Dixon; Masoom Haider; Michele Molinari; Caroline Reinhold; Morris Sherman
Journal:  AJR Am J Roentgenol       Date:  2015-03       Impact factor: 3.959

Review 3.  Pancreatic Ductal Adenocarcinoma and Its Variants.

Authors:  Claudio Luchini; Paola Capelli; Aldo Scarpa
Journal:  Surg Pathol Clin       Date:  2016-10-12

Review 4.  Pancreatic cancer.

Authors:  Audrey Vincent; Joseph Herman; Rich Schulick; Ralph H Hruban; Michael Goggins
Journal:  Lancet       Date:  2011-05-26       Impact factor: 79.321

5.  The diagnostic advantage of EOB-MR imaging over CT in the detection of liver metastasis in patients with potentially resectable pancreatic cancer.

Authors:  Takaaki Ito; Teiichi Sugiura; Yukiyasu Okamura; Yusuke Yamamoto; Ryo Ashida; Takeshi Aramaki; Masahiro Endo; Katsuhiko Uesaka
Journal:  Pancreatology       Date:  2017-03-08       Impact factor: 3.996

Review 6.  Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer.

Authors:  Victoria B Allen; Kurinchi Selvan Gurusamy; Yemisi Takwoingi; Amun Kalia; Brian R Davidson
Journal:  Cochrane Database Syst Rev       Date:  2016-07-06

7.  Incidence and risk factors for abdominal occult metastatic disease in patients with pancreatic adenocarcinoma.

Authors:  Georgios Gemenetzis; Vincent P Groot; Alex B Blair; Ding Ding; Sameer S Thakker; Elliot K Fishman; John L Cameron; Martin A Makary; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  J Surg Oncol       Date:  2018-10-31       Impact factor: 3.454

8.  Contrast-enhanced CT in determining resectability in patients with pancreatic carcinoma: a meta-analysis of the positive predictive values of CT.

Authors:  Inne Somers; Shandra Bipat
Journal:  Eur Radiol       Date:  2017-01-16       Impact factor: 5.315

9.  Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer.

Authors:  Xinchun Liu; Yue Fu; Qiuyang Chen; Junli Wu; Wentao Gao; Kuirong Jiang; Yi Miao; Jishu Wei
Journal:  BMC Gastroenterol       Date:  2018-11-06       Impact factor: 3.067

Review 10.  Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes.

Authors:  Andrew McGuigan; Paul Kelly; Richard C Turkington; Claire Jones; Helen G Coleman; R Stephen McCain
Journal:  World J Gastroenterol       Date:  2018-11-21       Impact factor: 5.742

View more
  2 in total

Review 1.  Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine.

Authors:  Federica Vernuccio; Carlo Messina; Valeria Merz; Roberto Cannella; Massimo Midiri
Journal:  Diagnostics (Basel)       Date:  2021-11-22

Review 2.  Magnetic Fields and Cancer: Epidemiology, Cellular Biology, and Theranostics.

Authors:  Massimo E Maffei
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.